- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
- Interventions
- Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
- Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–83
of 83
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia
- Interventions
- Regadenoson, Symptom-limited exercise
- Drug · Other
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Healthy Volunteers
- Interventions
- Regadenoson, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Artery Disease
- Interventions
- Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT, Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
- Drug
- Lead sponsor
- Cardiovascular Imaging Technologies
- Industry
- Eligibility
- 35 Years to 90 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
- Interventions
- Quantitative Myocardial Blood Flow Evaluation, Qualitative Myocardial Blood Flow Evaluation, Gadavist, Vasodilator, Blood draw for the laboratory assessment
- Diagnostic Test · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson, Adenosine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Sickle Cell Disease
- Interventions
- MRI, Transthoracic Echocardiography, tonometry, EKG
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Artery Disease
- Interventions
- PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation, Regadenoson
- Diagnostic Test · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
- Interventions
- Regadenoson, Dobutamine
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson (Lexiscan) [muti-detector computed tomography]
- Device
- Lead sponsor
- Tennessee Heart and Vascular Institute, P.C.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Hendersonville, Tennessee